FDA

Rahul Gosain: Trastuzumab Deruxtecan now is FDA approved, Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02

Rahul Gosain, Co-Founder of Oncology Brothers podcast and Director of Regional Infusion Services and Medical Director at Wilmot Cancer Institute, recently shared on LinkedIn:

“Trastuzumab Deruxtecan now FDA approved for pan-tumor with HER2 IHC3 and solid tumors who have received prior systemic treatment and have no alternative treatment options.

Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02:

  • Dose 5.4 mg/kg
  • Common AE: fatigue, decreased counts and nausea. ILD can be fatal.”

Rahul Gosain: Trastuzumab Deruxtecan now is FDA approved, Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02

Source: Rahul Gosain/LinkedIn

cancer DESTINY-CRC02 DESTINY-Lung01 DESTINY-PanTumor02 fatigue FDA HER2 IHC3 nausea OncoDaily Oncology pan-tumor Rahul Gosain solid tumors TDxd Trastuzumab deruxtecan